地塞米松与倍他米松用于早产的网状Meta分析
该系统评价与网状Meta分析纳入45项试验(11227名妇女和11878名婴儿),比较地塞米松与倍他米松用于早产的效果。两者在新生儿死亡、神经发育障碍、脑室内出血和出生体重上无重要差异,但在绒毛膜羊膜炎、胎儿死亡、产褥期脓毒症和呼吸窘迫综合征上虽无统计学显著差异,却存在潜在临床重要差异。
要点
- 地塞米松与倍他米松在新生儿死亡、神经发育障碍、脑室内出血和出生体重上无重要差异。
- 绒毛膜羊膜炎、胎儿死亡、产褥期脓毒症和呼吸窘迫综合征无统计学显著差异,但可能有潜在临床重要差异。
- 与安慰剂或无治疗相比,皮质类固醇对多数新生儿和儿童相关结局有效。
核心结论
- 与安慰剂或无治疗相比,皮质类固醇对大多数新生儿和儿童相关结局有效。
- 地塞米松与倍他米松在新生儿死亡、神经发育障碍、脑室内出血和出生体重上无重要差异。
- 绒毛膜羊膜炎、胎儿死亡、子宫内膜炎或产褥期脓毒症和呼吸窘迫综合征无统计学显著差异,但存在潜在重要差异。
研究设计与样本
- 纳入比较任何皮质类固醇之间或与安慰剂比较的随机或半随机对照试验,任何剂量,用于早产。
- 共纳入45项试验,11227名妇女和11878名婴儿。
- 采用随机效应配对Meta分析和贝叶斯网状Meta分析。
主要发现
- 新生儿死亡:地塞米松 vs 倍他米松 OR 1.05(95%CI 0.62-1.84),中等确定性证据。
- 神经发育障碍:OR 1.03(95%CI 0.80-1.33),中等确定性证据。
- 脑室内出血:OR 1.04(95%CI 0.56-1.78),低确定性证据。
- 出生体重:+5.29 g(95%CI -49.79至58.97),高确定性证据。
- 绒毛膜羊膜炎:OR 0.70(95%CI 0.45-1.06),中等确定性证据;胎儿死亡:OR 0.81(95%CI 0.24-2.41),低确定性证据;产褥期脓毒症:OR 2.04(95%CI 0.72-6.06),低确定性证据;呼吸窘迫综合征:OR 1.34(95%CI 0.96-2.11),中等确定性证据。
临床怎么用
- 对于有早产风险的妇女,皮质类固醇治疗对多数新生儿和儿童相关结局有效。
- 地塞米松与倍他米松在主要新生儿结局上无重要差异,选择时可综合考虑其他因素。
局限性
- 需要进一步研究以提高证据确定性并为卫生政策提供信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the comparative clinical effectiveness and safety of dexamethasone vs betamethasone for preterm birth. DATA SOURCES: The sources searched were MEDLINE, EMBASE, Cochrane Library, LILACS, ClinicalTrials.gov, and International Clinical Trials Registry Platform without language restrictions until October 2019 in addition to the reference lists of included studies. Field experts were also contacted. STUDY ELIGIBILITY CRITERIA: Randomized or quasi-randomized controlled trials comparing any corticosteroids against each other or against placebo at any dose for preterm birth were included in the study. METHODS: Three researchers independently selected and extracted data and assessed the risk of bias of the included studies by using Early Review Organizing Software and Covidence software. Random-effects pairwise meta-analysis and Bayesian network meta-analysis were performed. The primary outcomes were chorioamnionitis, endometritis or puerperal sepsis, neonatal death, respiratory distress syndrome, and neurodevelopmental disability. RESULTS: A total of 45 trials (11,227 women and 11,878 infants) were included in the study. No clinical or statistical difference was found between dexamethasone and betamethasone in neonatal death (odds ratio, 1.05; 95% confidence interval, 0.62-1.84; moderate-certainty evidence), neurodevelopmental disability (odds ratio, 1.03; 95% confidence interval, 0.80-1.33; moderate-certainty evidence), intraventricular hemorrhage (odds ratio, 1.04; 95% confidence interval, 0.56-1.78); low-certainty evidence), or birthweight (+5.29 g; 95% confidence interval, -49.79 to 58.97; high-certainty evidence). There was no statistically significant difference, but a potentially clinically important effect was found between dexamethasone and betamethasone in chorioamnionitis (odds ratio, 0.70; 95% confidence interval, 0.45-1.06; moderate-certainty evidence), fetal death (odds ratio, 0.81; 95% confidence interval, 0.24-2.41; low-certainty evidence), puerperal sepsis (odds ratio, 2.04; 95% confidence interval, 0.72-6.06; low-certainty evidence), and respiratory distress syndrome (odds ratio, 1.34; 95% confidence interval, 0.96-2.11; moderate-certainty evidence). Meta-regression, subgroup, and sensitivity analyses did not reveal important changes regarding the main analysis. CONCLUSION: Corticosteroids have proven effective for most neonatal and child-relevant outcomes compared with placebo or no treatment for women at risk of preterm birth. No important difference was found on neonatal death, neurodevelopmental disability, intraventricular hemorrhage, and birthweight between corticosteroids, and there was no statistically significant difference, but a potentially important difference was found in chorioamnionitis, fetal death, endometritis or puerperal sepsis, and respiratory distress syndrome. Further research is warranted to improve the certainty of evidence and inform health policies.
引用
- Ciapponi A, Klein K, Colaci D, et al. Dexamethasone versus betamethasone for preterm birth: a systematic review and network meta-analysis. Am J Obstet Gynecol MFM. 2021. PMID: 33482400. doi:10.1016/j.ajogmf.2021.100312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。